Head-to-Head: which drug works better for psoriatic arthritis in the real world?
NCT ID NCT07386717
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 70 people with psoriatic arthritis to compare two drug types: upadacitinib and IL-17 inhibitors. Researchers tracked joint and skin symptoms over 24 weeks in routine care. The goal is to see which works better in real life, helping doctors personalize treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib and interleukin-17 inhibitors
What this could lead to
If this study shows one drug works better in real life, it could help doctors choose the best treatment for each person with psoriatic arthritis.
What could go wrong
This is a small, completed observational study, not a large trial. Results may not apply to everyone, and the 24-week follow-up is too short to see long-term effects or rare side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, China